Consensus Pathways for Coronary Microvascular Disease Management

Abstract

Coronary microvascular disease (CMD) represents a clinically significant yet often under-recognized contributor to ischemic heart disease and adverse cardiovascular outcomes. Despite advances in macrovascular coronary imaging and intervention, CMD poses unique diagnostic and management challenges due to its complex pathophysiology, heterogeneous clinical presentation, and the absence of obstructive epicardial coronary artery disease. This review synthesizes current evidence, recent guideline recommendations, and emerging therapies, providing a structured, practical approach for clinicians managing CMD. We address epidemiology, underlying mechanisms, risk factors, clinical features, diagnostic strategies, and consensus-based management pathways, emphasizing the importance of multidisciplinary care and individualized treatment plans.

Introduction

Coronary microvascular disease has garnered increasing attention over the past decade as a distinct entity contributing to myocardial ischemia, particularly in patients without significant epicardial coronary artery stenosis. Advances in cardiac imaging and functional assessment have illuminated the burden of CMD, which often escapes detection by conventional angiography. CMD is characterized by impaired regulation of coronary microvascular blood flow, leading to inadequate myocardial perfusion and angina in the absence of obstructive coronary artery disease. With a rising prevalence of non-obstructive ischemic syndromes, understanding CMD is paramount for optimizing patient outcomes and reducing the global burden of cardiovascular disease.

Epidemiology / Disease Burden

CMD affects a substantial proportion of patients presenting with chest pain and evidence of myocardial ischemia, with studies estimating its prevalence to be as high as 50% among individuals undergoing coronary angiography for suspected ischemic heart disease. It is particularly prevalent among women, patients with diabetes, hypertension, and metabolic syndrome. CMD contributes to a spectrum of pathologies, including ischemia with non-obstructive coronary arteries (INOCA) and heart failure with preserved ejection fraction (HFpEF). The disease is associated with increased risks of recurrent angina, hospitalization, major adverse cardiovascular events (MACE), and impaired quality of life, underscoring the need for heightened clinical vigilance and targeted management strategies.

Pathophysiology

The pathogenesis of CMD is multifactorial, involving structural and functional abnormalities of the coronary microcirculation. Endothelial dysfunction, impaired vasodilation, increased vascular stiffness, microvascular remodeling, and perivascular inflammation are key contributors. The imbalance between vasodilatory and vasoconstrictor factors, often exacerbated by oxidative stress and neurohormonal activation, leads to decreased coronary flow reserve (CFR) and microvascular spasm. Microvascular rarefaction and extravascular compressive forces further compromise myocardial perfusion. The heterogeneity in mechanisms may explain the variable clinical manifestations and therapeutic responses observed in CMD patients.

Risk Factors

CMD shares many traditional cardiovascular risk factors with macrovascular coronary artery disease. These include advanced age, female sex, hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking. Additional risk factors specific to CMD encompass systemic inflammatory states, autoimmune diseases, and hormonal influences, particularly in postmenopausal women. The presence of metabolic syndrome and chronic kidney disease further increases susceptibility to CMD. Identification and modification of these risk factors are crucial in the comprehensive management of affected patients.

Clinical Features

Patients with CMD most commonly present with exertional or rest angina, often indistinguishable from symptoms caused by obstructive coronary artery disease. Other manifestations may include dyspnea, fatigue, and atypical chest discomfort. Notably, CMD is responsible for a significant proportion of angina cases in women and younger individuals. The symptoms are frequently persistent and refractory to standard antianginal therapies, leading to recurrent healthcare visits and diminished quality of life. A high index of suspicion is necessary, especially in patients with ischemic symptoms but normal or near-normal coronary angiograms.

Diagnosis

Accurate diagnosis of CMD requires a multimodal approach integrating clinical assessment, non-invasive and invasive testing. Non-invasive modalities include stress echocardiography, cardiac magnetic resonance imaging (CMR) with perfusion analysis, and positron emission tomography (PET) to assess myocardial blood flow and CFR. Invasive coronary function testing (CFT), using coronary flow reserve, index of microcirculatory resistance (IMR), and acetylcholine or adenosine provocation tests, remains the gold standard for definitive diagnosis. Exclusion of obstructive coronary artery disease through coronary angiography or computed tomography angiography (CTA) is essential. Emerging biomarkers and imaging technologies continue to refine the diagnostic algorithm for CMD.

Treatment & Management

Management of CMD is multifaceted and should be individualized based on underlying mechanisms, comorbidities, and symptom severity. Lifestyle modification and aggressive risk factor control (blood pressure, glycemic, lipid management, smoking cessation) form the cornerstone of therapy. Pharmacological interventions commonly include beta-blockers, calcium channel blockers, and long-acting nitrates, though response may be variable. Agents targeting endothelial dysfunction (e.g., ACE inhibitors, statins, ranolazine) show promise, particularly in patients with impaired vasodilation. For refractory symptoms, consideration of novel therapies and referral to specialized centers may be warranted. Multidisciplinary care, patient education, and psychosocial support are critical for optimizing long-term outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in the understanding and management of CMD. Novel diagnostic tools, such as thermodilution-based measurements and advanced imaging protocols, enhance identification of microvascular dysfunction. Pharmacotherapeutic innovations, including endothelin receptor antagonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and anti-inflammatory agents, are under investigation for their potential benefits in CMD. Interventional approaches, such as coronary sinus reducers, offer promise for selected patients with refractory angina. Ongoing clinical trials and translational research are expected to further expand the therapeutic armamentarium in the near future.

Guideline Recommendations

Consensus guidelines from major cardiology societies now recognize CMD as a clinically relevant entity warranting systematic evaluation and management. The European Society of Cardiology (ESC) and American Heart Association (AHA) recommend the use of non-invasive and invasive functional testing for diagnosis in patients with angina and no obstructive coronary artery disease. Risk factor modification, individualized antianginal therapy, and regular follow-up are emphasized. Multidisciplinary collaboration and research participation are encouraged, given the evolving evidence base and ongoing therapeutic trials.

Conclusion

CMD represents a significant cause of myocardial ischemia with substantial clinical and prognostic implications. Recent consensus pathways highlight the importance of comprehensive assessment, targeted risk factor modification, and individualized therapy. Advances in diagnostic and therapeutic modalities are poised to improve patient outcomes, but ongoing research and guideline refinement remain essential. Enhanced awareness and systematic management of CMD can mitigate its burden and improve quality of life for affected individuals.